Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2043-2048

  Wang, Linhui ^a   Huang, Ting ^a   Chen, Wei ^a   Gao, Xiaofeng ^a   Zhou, Tie ^a   Wu, Zhenjie ^a   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CXCR4; Renal cell carcinoma; RNA interference

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SMALL INTERFERING RNA;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868095010     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2028     Document Type: Conference Paper

References (37)

1. Godley P and Kim SW: Renal cell carcinoma. Curr Opin Oncol 14:280-285, 2002. (Pubitemid 34492859)
2. Fishman M and Seigne J: Immunotherapy of metastatic renal cell cancer. Cancer Control 9:293-304, 2002. (Pubitemid 34921035)
3. Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev 13:143-154, 2002. (Pubitemid 34229389)
4. Navarini-Meury AA and Conrad CC: Melanoma and innate immunity-active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 19:84-91, 2009.
5. Skommer J, Wlodkowic D and Pelkonen J: CXCR4 expression during tumour cell death. Leuk Res 31:1155-1156, 2007.
6. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761-1767, 2006. (Pubitemid 43289351)
7. Broxmeyer HE, Orschell CM and Clapp DW: Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1293-1305, 2005.
8. Labrosse B, Brelot A and Heveker N: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381-6388, 1998. (Pubitemid 28323949)
9. Hendrix CW, Collier AC, Lederman MM, et al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37:1253-1262, 2004. (Pubitemid 39281506)
10. Paul S, Mancuso P, Rabascio C, et al: In Vitro and Preclinical Activity of the Novel AMD3100 CXCR4 Antagonist in Lymphoma Models. In: American Society of Hematology Annual Meeting, 2002; Philadelphia, PA, USA: Blood, 2002.
11. Duxbury MS and Whang EE: RNA interference: a practical approach. J Surg Res 117:339-344, 2004. (Pubitemid 38393660)
12. Wang L, Wang Z, Yang B, et al: CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol Rep 22:1333-1339, 2009.
13. Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 12:121-127, 2000. (Pubitemid 30398626)
14. Zlotnik A: Chemokines and cancer. Int J Cancer 119:2026-2029, 2006. (Pubitemid 44423657)
15. Kim J, Takeuchi H, Lam ST, et al: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744-2753, 2005. (Pubitemid 46179464)
16. Hiller DJ, Li BD and Chu QD: CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy. J Surg Res 166:14-18, 2011.
17. Xie L, Wei J, Qian X, et al: CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer. Anticancer Res 30:2209-2216, 2010.
18. Spoo AC, Lubbert M and Wierda WG: CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109:786-791, 2007. (Pubitemid 46105982)
19. Laverdiere C, Hoang BH and Yang R: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11:2561-2567, 2005. (Pubitemid 40569454)
20. Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89:462-473, 2003. (Pubitemid 36648768)
21. Zagzag D, Krishnamachary B, Yee H, et al: Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-offunction induces expression of a ligand and its receptor. Cancer Res 65:6178-6188, 2005. (Pubitemid 40994403)
22. Thomas C W, Claudine G, Stefan B, et al: Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol 2008:1-6, 2008.
23. Wang LH, Liu Q, Xu B, et al: Identification of nuclear localization sequence of CXCR4 in renal cell carcinoma by constructing expression plasmids of different deletants. Plasmid 63:68-72, 2010.
24. Lin SY, Makino K, Xia W, et al: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802-808, 2001. (Pubitemid 32842685)
25. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996.
26. Khan MZ, Shimizu S, Patel JP, et al: Regulation of neuronal P53 activity by CXCR 4. Mol Cell Neurosci 30:58-66, 2005. (Pubitemid 41133340)
27. Gerlach LO, Skerlj RT, Bridger GJ, et al: Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276:14153-14160, 2001.
28. Dewan MZ, Ahmed S, Iwasaki Y, et al: Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60:273-276, 2006. (Pubitemid 44223937)
29. Burger M, Glodek A, Hartmann T, et al: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22:8093-8101, 2003. (Pubitemid 37487300)
30. Hartmann TN, Burger JA, Glodek A, et al: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24:4462-4471, 2005. (Pubitemid 40961769)
31. Chao DT and Korsmeyer SJ: Bcl-2 family: regulators of cell death. Annu Rev Immunol 16:395-419, 1998. (Pubitemid 28183370)
32. Carmen HL, Jaris V, Laura HI, et al: CXCL12/CXCR4 signaling promotes human thymic dendritic cell survival regulating the Bcl-2/Bax ratio. Immunol Lett 120:72-78, 2008.
33. Zheng H, Dai T, Zhou B, et al: SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 201:36-42, 2008.
34. Gao F, Gao E, Yue T L, et al: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497-1502, 2002. (Pubitemid 34263284)
35. Yin G, Li LY, Qu M, Luo HB, Wang JZ and Zhou XW: Upregulation of AKT attenuates amyloid-β-induced cell apoptosis. J Alzheimers Dis 25:337-345, 2011.
36. New DC, Wu K, Kwok AW, et al: G protein-coupled receptorinduced Akt activity in cellular proliferation and apoptosis. FEBS J 274:6025-6036, 2007 (Pubitemid 350135324)
37. Ljungberg B, Cowan NC, Hanbury DC, et al: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:401-402, 2010.